125 related articles for article (PubMed ID: 31568268)
21. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
Schillaci O; Calabria F; Tavolozza M; Caracciolo CR; Finazzi Agrò E; Miano R; Orlacchio A; Danieli R; Simonetti G
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):589-96. PubMed ID: 22231016
[TBL] [Abstract][Full Text] [Related]
22. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
23. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.
García-Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2467-2483. PubMed ID: 38520513
[TBL] [Abstract][Full Text] [Related]
24. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
Cimitan M; Bortolus R; Morassut S; Canzonieri V; Garbeglio A; Baresic T; Borsatti E; Drigo A; Trovò MG
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1387-98. PubMed ID: 16865395
[TBL] [Abstract][Full Text] [Related]
25. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
26. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
Tan H; Joseph D; Loh NK; McCarthy M; Leong E; Siew T; Segard T; Morandeau L; Trevenen M; Francis RJ
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
[TBL] [Abstract][Full Text] [Related]
28. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer.
Pizzuto DA; Annunziata S; Ieria FP; Caldarella C; Isgrò MA; Lanni V; Bencivenga G; Rufini V; Giordano A
Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):387-393. PubMed ID: 29345442
[TBL] [Abstract][Full Text] [Related]
29. 18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies.
Jiménez Londoño GA; García Vicente AM; Noriega Álvarez E; Pena Pardo FJ; Amo-Salas M; López Guerrero MA; Fúnez Mayorga F; Soriano Castrejón ÁM
Nucl Med Commun; 2020 Jul; 41(7):674-681. PubMed ID: 32404644
[TBL] [Abstract][Full Text] [Related]
30. Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.
Bertagna F; Abuhilal M; Bosio G; Simeone C; Rossini P; Pizzocaro C; Orlando E; Finamanti M; Biasiotto G; Rodella C; Cosciani Cunico S; Giubbini R
Jpn J Radiol; 2011 Jul; 29(6):394-404. PubMed ID: 21786095
[TBL] [Abstract][Full Text] [Related]
31. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
Breeuwsma AJ; Pruim J; van den Bergh AC; Leliveld AM; Nijman RJ; Dierckx RA; de Jong IJ
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):160-4. PubMed ID: 19783375
[TBL] [Abstract][Full Text] [Related]
32. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
[TBL] [Abstract][Full Text] [Related]
33. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
34. Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
Haroon A; Syed R; Endozo R; Allie R; Freeman A; Emberton M; Bomanji J
Nucl Med Commun; 2017 May; 38(5):407-414. PubMed ID: 28379896
[TBL] [Abstract][Full Text] [Related]
35. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G; Autret A; Guibert-Broudic M; Dubergé T; Zemmour C; Carrier P; Salem N; Badinand D; Cartier L; Gross E; Walz J; Pignot G; Brenot-Rossi I
Clin Genitourin Cancer; 2021 Aug; 19(4):346-353. PubMed ID: 33849812
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
39. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.
Kwee SA; Coel MN; Lim J
Ann Nucl Med; 2012 Jul; 26(6):501-7. PubMed ID: 22549847
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level < 5 ng/ml].
Rioja Zuazu J; Rodríguez M; Rincón Mayans A; Sansi AS; Zudaire Bergera JJ; Martínez-Monge R; Richter JA; Berián Polo JM
Actas Urol Esp; 2009 Sep; 33(8):844-52. PubMed ID: 19900376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
